The article provides an overview of analyst ratings for Regenxbio in the last quarter. The mixed ratings, with 1 bullish, 3 somewhat bullish, and 1 indifferent, indicate that there is no clear consensus on the stock's short-term direction. The average 12-month price target of $40.4 represents a 6.05% decrease from the previous average, suggesting that analysts have slightly lowered their expectations for the stock. However, the overall impact on the stock price in the short term is likely to be neutral, as the mixed ratings do not provide a strong directional signal.